Expertise in
1
conditions

Takashi Fujita

Kusatsu, JP 
Expertise in
1
conditions
Kusatsu, JP 
OverviewLocationsClinical Research

Overview

Takashi Fujita practices in Kusatsu, Japan. Mr. Fujita is highly rated in 1 condition, according to our data. His top areas of expertise are Singleton-Merten Syndrome, Aase Syndrome, Aicardi-Goutieres Syndrome, and Severe Fever with Thrombocytopenia Syndrome.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Kusatsu, 5258577, Japan
Other Locations
Kyoto, Japan
Nagoya, Japan
Tokyo University Of Technology 1401-1 Katakura Hachioji Tokyo 192-0982 Japan, Tokyo, 1920982, Japan
5258577, Japan
Uji, 6110011, Japan
Tokai, 4768588, Japan
Shimotsuke, Japan
Tochigi, 3290498, Japan
Kawahara, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

116 Total Publications

Local activation of mutant RIG-I by short noncoding Y-RNA in the kidney triggers lethal nephritis.
Local activation of mutant RIG-I by short noncoding Y-RNA in the kidney triggers lethal nephritis.
Journal: Science immunology
Published: October 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fujita's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile